{
    "info": {
        "nct_id": "NCT04519879",
        "official_title": "A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance",
        "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* For therapy naive favorable risk prostate cancer (cohort 2 only): agreement to undergo baseline and 48 week prostate biopsy\n* Willing to forego non-study supplements containing mushroom for the duration of the study\n* Eastern Cooperative Oncology Group (ECOG) =< 2\n* Histologically or cytologically confirmed history of adenocarcinoma of the prostate\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: PSA failure defined as:\n\n  * PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy, OR\n  * PSA increase of 2.0 ng/mL above post-therapy nadir if other primary local therapy was used instead of prostatectomy\n  * NOTE: PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Testosterone levels > 50 ng/dL\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Received any number of primary local therapies, defined as:\n\n  * Radical prostatectomy\n  * External beam radiation therapy\n  * Radioactive seed implantation\n  * Cryotherapy\n  * High-intensity focused ultrasound (HIFU)\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy. Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy. If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan\n* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adenocarcinoma of the prostate diagnosed =< 12 months of protocol screening and has elected active surveillance as preferred management plan OR already on active surveillance\n* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Clinical stage T1c-T2a as defined below:\n\n  * T1c: Tumor identified by needle biopsy found in one or both sides, but not palpable\n  * T2a: Tumor involves one-half of one side or less\n* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)\n* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adequate biopsy of at least 10 biopsy cores\n* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: No prior therapy for prostate cancer defined as:\n\n  * Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)\n  * Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy). Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed\n* Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)\n* Hemoglobin > 8 g/dL (within 28 days prior to day 1 of protocol therapy)\n* Aspartate aminotransferase, alanine aminotransferase, < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)\n* Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)\n* Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Other concomitant investigational anti-cancer therapy/ vaccines/biologics, corticosteroids with > 10 mg of prednisone equivalent dose\n* Therapy with mushroom supplements within last 3 months of randomization\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months or within 6 months prior to day 1 of protocol therapy\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy\n* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy):\n\n  * Chemotherapy\n  * Androgen deprivation therapy\n  * Immunotherapy\n  * Targeted therapy\n* Known history of allergic reaction to mushrooms\n* Clinically significant uncontrolled illness\n* Active infection requiring treatment\n* Uncontrolled congestive heart failure, cardiac arrhythmia\n* History of other primary non-skin malignancy within previous 2 years unless treated with curative intent and in remission\n* Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Cryotherapy",
            "criterions": [
                {
                    "exact_snippets": "Cryotherapy",
                    "criterion": "cryotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history or receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* External beam radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "External beam radiation therapy",
                    "criterion": "external beam radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: PSA failure defined as:",
            "criterions": [
                {
                    "exact_snippets": "BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY",
                    "criterion": "cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": "biochemically recurrent prostate cancer cohort (cohort 1)"
                        }
                    ]
                },
                {
                    "exact_snippets": "PSA failure defined as",
                    "criterion": "PSA failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)",
            "criterions": [
                {
                    "exact_snippets": "Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": ""
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "grade group",
                            "expected_value": "1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Gleason 3+4 (grade group 2)",
                    "criterion": "Gleason score pattern",
                    "requirements": [
                        {
                            "requirement_type": "pattern",
                            "expected_value": "3+4"
                        },
                        {
                            "requirement_type": "grade group",
                            "expected_value": "2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adenocarcinoma of the prostate diagnosed =< 12 months of protocol screening and has elected active surveillance as preferred management plan OR already on active surveillance",
            "criterions": [
                {
                    "exact_snippets": "Adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosed =< 12 months of protocol screening",
                    "criterion": "time since diagnosis of adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has elected active surveillance as preferred management plan OR already on active surveillance",
                    "criterion": "active surveillance management plan",
                    "requirements": [
                        {
                            "requirement_type": "management plan",
                            "expected_value": "active surveillance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to forego non-study supplements containing mushroom for the duration of the study",
            "criterions": [
                {
                    "exact_snippets": "Willing to forego non-study supplements containing mushroom for the duration of the study",
                    "criterion": "use of non-study supplements containing mushroom",
                    "requirements": [
                        {
                            "requirement_type": "willingness to forego",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA increase of 2.0 ng/mL above post-therapy nadir if other primary local therapy was used instead of prostatectomy",
            "criterions": [
                {
                    "exact_snippets": "PSA increase of 2.0 ng/mL above post-therapy nadir",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "increase_above_nadir",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if other primary local therapy was used instead of prostatectomy",
                    "criterion": "primary local therapy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "other than prostatectomy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study",
            "criterions": [
                {
                    "exact_snippets": "Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study",
                    "criterion": "neoadjuvant/adjuvant cytotoxic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion time before study day 1",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Clinical stage T1c-T2a as defined below:",
            "criterions": [
                {
                    "exact_snippets": "THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY",
                    "criterion": "cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort",
                            "expected_value": "THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinical stage T1c-T2a",
                    "criterion": "clinical stage of prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "T1c"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "T2a"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radioactive seed implantation",
            "criterions": [
                {
                    "exact_snippets": "Radioactive seed implantation",
                    "criterion": "radioactive seed implantation",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase, alanine aminotransferase, < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase ... < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase ... < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 8 g/dL (within 28 days prior to day 1 of protocol therapy)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Received any number of primary local therapies, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Received any number of primary local therapies",
                    "criterion": "primary local therapies",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy. Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study",
            "criterions": [
                {
                    "exact_snippets": "May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy",
                    "criterion": "neoadjuvant/adjuvant androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "conjunction_with_primary_local_therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study",
                    "criterion": "androgen deprivation therapy completion",
                    "requirements": [
                        {
                            "requirement_type": "time_since_completion",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "reference_point",
                            "expected_value": "from day (D)1 of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Testosterone levels > 50 ng/dL",
            "criterions": [
                {
                    "exact_snippets": "Testosterone levels > 50 ng/dL",
                    "criterion": "testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adequate biopsy of at least 10 biopsy cores",
            "criterions": [
                {
                    "exact_snippets": "Adequate biopsy of at least 10 biopsy cores",
                    "criterion": "biopsy cores",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "cores"
                            }
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For therapy naive favorable risk prostate cancer (cohort 2 only): agreement to undergo baseline and 48 week prostate biopsy",
            "criterions": [
                {
                    "exact_snippets": "therapy naive favorable risk prostate cancer (cohort 2 only)",
                    "criterion": "prostate cancer risk group",
                    "requirements": [
                        {
                            "requirement_type": "risk group",
                            "expected_value": "favorable"
                        },
                        {
                            "requirement_type": "therapy naive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to undergo baseline and 48 week prostate biopsy",
                    "criterion": "prostate biopsy",
                    "requirements": [
                        {
                            "requirement_type": "agreement to undergo",
                            "expected_value": [
                                "baseline",
                                "48 week"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* T2a: Tumor involves one-half of one side or less",
            "criterions": [
                {
                    "exact_snippets": "T2a: Tumor involves one-half of one side or less",
                    "criterion": "tumor involvement of one side",
                    "requirements": [
                        {
                            "requirement_type": "extent of involvement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.5,
                                "unit": "side"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed history of adenocarcinoma of the prostate",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed history of adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy). Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed",
            "criterions": [
                {
                    "exact_snippets": "Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy)",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment types",
                            "expected_value": [
                                "hormonal",
                                "immunotherapy",
                                "targeted",
                                "chemotherapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed",
                    "criterion": "prior use of 5-alpha reductase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment types",
                            "expected_value": [
                                "finasteride",
                                "dutasteride",
                                "5-alpha reductase inhibitor"
                            ]
                        },
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)",
            "criterions": [
                {
                    "exact_snippets": "Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "/mm^3"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of the participant and/or legally authorized representative",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of the participant and/or legally authorized representative",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "participant",
                                "legally authorized representative"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)",
            "criterions": [
                {
                    "exact_snippets": "Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)",
                    "criterion": "local therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "surgery",
                                "radiation",
                                "focal therapy (cryoablation, HIFU, light)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* T1c: Tumor identified by needle biopsy found in one or both sides, but not palpable",
            "criterions": [
                {
                    "exact_snippets": "Tumor identified by needle biopsy",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "identification_method",
                            "expected_value": "needle biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "found in one or both sides",
                    "criterion": "tumor laterality",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "one side",
                                "both sides"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not palpable",
                    "criterion": "tumor palpability",
                    "requirements": [
                        {
                            "requirement_type": "palpability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High-intensity focused ultrasound (HIFU)",
            "criterions": [
                {
                    "exact_snippets": "High-intensity focused ultrasound (HIFU)",
                    "criterion": "high-intensity focused ultrasound (HIFU)",
                    "requirements": [
                        {
                            "requirement_type": "exposure or treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radical prostatectomy",
            "criterions": [
                {
                    "exact_snippets": "Radical prostatectomy",
                    "criterion": "radical prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "history/procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy, OR",
            "criterions": [
                {
                    "exact_snippets": "PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.2,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "trend",
                            "expected_value": "increased above nadir"
                        }
                    ]
                },
                {
                    "exact_snippets": "following prostatectomy",
                    "criterion": "history of prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy. If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan",
            "criterions": [
                {
                    "exact_snippets": "No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "evidence (clinical or radiographic)",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan",
                    "criterion": "metastatic disease on CT scan (or MRI) and bone scan",
                    "requirements": [
                        {
                            "requirement_type": "evidence (CT scan or MRI and bone scan)",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart",
            "criterions": [
                {
                    "exact_snippets": "PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart",
                    "criterion": "PSA value",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": "increasing"
                        },
                        {
                            "requirement_type": "measurement_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "measurements"
                            }
                        },
                        {
                            "requirement_type": "measurement_interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: No prior therapy for prostate cancer defined as:",
            "criterions": [
                {
                    "exact_snippets": "No prior therapy for prostate cancer",
                    "criterion": "prior therapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "Targeted therapy",
                    "criterion": "targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of allergic reaction to mushrooms",
            "criterions": [
                {
                    "exact_snippets": "Known history of allergic reaction to mushrooms",
                    "criterion": "allergic reaction to mushrooms",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy):",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy)",
                    "criterion": "prior therapy for recurrent prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled congestive heart failure, cardiac arrhythmia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Androgen deprivation therapy",
            "criterions": [
                {
                    "exact_snippets": "Androgen deprivation therapy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures",
                    "criterion": "other condition contraindicating participation due to safety concerns",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant uncontrolled illness",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "clinically significant uncontrolled illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Therapy with mushroom supplements within last 3 months of randomization",
            "criterions": [
                {
                    "exact_snippets": "Therapy with mushroom supplements within last 3 months of randomization",
                    "criterion": "mushroom supplement therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other concomitant investigational anti-cancer therapy/ vaccines/biologics, corticosteroids with > 10 mg of prednisone equivalent dose",
            "criterions": [
                {
                    "exact_snippets": "Other concomitant investigational anti-cancer therapy",
                    "criterion": "concomitant investigational anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vaccines/biologics",
                    "criterion": "concomitant investigational vaccines or biologics",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corticosteroids with > 10 mg of prednisone equivalent dose",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy",
                    "criterion": "neoadjuvant/adjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other primary non-skin malignancy within previous 2 years unless treated with curative intent and in remission",
            "criterions": [
                {
                    "exact_snippets": "History of other primary non-skin malignancy within previous 2 years",
                    "criterion": "history of other primary non-skin malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "site",
                            "expected_value": "non-skin"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless treated with curative intent and in remission",
                    "criterion": "other primary non-skin malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "remission status",
                            "expected_value": "in remission"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring treatment",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring treatment",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's judgment of participant suitability",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "suitable for study procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunotherapy",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months or within 6 months prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months",
                    "criterion": "neoadjuvant/adjuvant androgen deprivation therapy duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Neoadjuvant/adjuvant androgen derivation therapy ... within 6 months prior to day 1 of protocol therapy",
                    "criterion": "neoadjuvant/adjuvant androgen deprivation therapy timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}